Related Experiment Video
Updated: Jun 16, 2026
Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
Published on: June 25, 2015
A Subunit Vaccine Candidate Composed of Mpox Virus A29L, M1R, A35R, and B6R Elicits Robust Immune Response in Mice
Xuetao Yang1,2, Xidan Yang1,2, Shouwen Du3
1School of Nursing, Southwest Medical University, Luzhou 646000, China.
Abstract:
With no specific antiviral drugs and preventive vaccines against Mpox virus (MPXV), the epidemic has led to the declaration of a Public Health Emergency of International Concern. As a developmental direction for new vaccines, studies of subunit vaccines based upon MPXV antigen proteins are lacking. In this study, A29L, M1R, A35R, and B6R of MPXV were expressed and purified from a prokaryotic system. The four MPXV antigen proteins in combination were mixed with aluminum hydroxide or CpG7909 as adjuvant, and subsequently used to inoculate mice. The results of enzyme-linked immunosorbent assay (ELISA), flow cytometry analyses, and enzyme-linked immunospot (ELISPOT) assays indicated that A29L, M1R, A35R, and B6R elicited high-level antigen-specific antibodies and CD4+ T cells-based cellular immune response in mice. Moreover, the results of virus neutralization assays suggested that sera from the mice immunized with four proteins elicited high neutralizing activities against the vaccinia virus. Notably, the results of ELISA, ELISPOT, and virus neutralization assays also showed that the CpG7909 adjuvant was more effective in inducing an immune response compared with the aluminum adjuvant. In summary, this study offers valuable insights for further studies of subunit vaccine candidates for the prevention of MPXV and other orthomyxoviruses.
Insights
Researchers developed a subunit vaccine candidate for Mpox virus (MPXV) using four key antigens (A29L, M1R, A35R, B6R). This vaccine induced strong antibody and T cell responses in mice, showing promise for MPXV prevention.
Area of Science:
- Virology and Immunology
- Vaccine Development
Background:
- Mpox virus (MPXV) poses a significant public health threat with no specific treatments or vaccines.
- Subunit vaccines are a promising avenue for MPXV prevention, but research on MPXV antigen proteins is limited.
Purpose of the Study:
- To investigate the immunogenicity of four MPXV antigen proteins (A29L, M1R, A35R, B6R) as a potential subunit vaccine.
- To evaluate the efficacy of different adjuvants (aluminum hydroxide and CpG7909) in enhancing the immune response.
Main Methods:
- Expression and purification of MPXV A29L, M1R, A35R, and B6R proteins from a prokaryotic system.
- Immunization of mice with protein combinations and adjuvants.
- Assessment of immune responses using ELISA, flow cytometry, ELISPOT, and virus neutralization assays.
Main Results:
- The four MPXV antigens successfully elicited high levels of antigen-specific antibodies and CD4+ T cell responses in mice.
- Immunized mice sera demonstrated significant neutralizing activity against vaccinia virus.
- CpG7909 adjuvant proved more effective than aluminum hydroxide in stimulating immune responses.
Conclusions:
- The study demonstrates the potential of A29L, M1R, A35R, and B6R as components of a subunit vaccine for MPXV.
- CpG7909 is a superior adjuvant for inducing robust immune responses against MPXV antigens.
- These findings provide a foundation for developing novel MPXV subunit vaccines and related orthomyxovirus preventatives.
More Related Videos
12:42Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
12:53Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development
Published on: March 16, 2022
